Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists
US11312683B2 · kind B2 · utility
0Cited by
17References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 26, 2020 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Mar 26, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D207/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.